Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 427 entries
View as:

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT03440372 Org: User:
Start: 02/27/18 End: 10/01/24 Due: 10/01/25

A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT01466725 Org: User:
Start: 11/01/11 End: 07/30/12 Due: 07/30/13

Expanded Access for Marizomib

Phase: N/A Priority: Normal
NCT ID: NCT04644107 Org: User:
Start: - End: - Due: -

Bioavailability of Enasidenib (CC-90007) Sprinkle Formulation Relative to the Reference Tablet Formulation and Effect of Food on the Pharmacokinetics of Sprinkle Formulation in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT04310527 Org: User:
Start: 10/09/19 End: 12/09/19 Due: 12/09/20

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

Phase: N/A Priority: Normal
NCT ID: NCT02935790 Org: User:
Start: 09/30/16 End: 04/07/17 Due: 04/07/18

Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00629473 Org: User:
Start: 07/31/07 End: 04/30/13 Due: 04/30/14

Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs)

Phase: N/A Priority: Normal
NCT ID: NCT04973280 Org: User:
Start: 07/26/21 End: 07/21/22 Due: 07/21/23

Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292

Phase: N/A Priority: Normal
NCT ID: NCT01692184 Org: User:
Start: 08/01/12 End: 10/08/12 Due: 10/08/13

Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

Phase: N/A Priority: Normal
NCT ID: NCT02447666 Org: User:
Start: 09/15/15 End: 05/24/19 Due: 05/24/20

A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.

Phase: N/A Priority: Normal
NCT ID: NCT02021500 Org: User:
Start: 01/02/14 End: 04/16/15 Due: 04/16/16

A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04860466 Org: User:
Start: 01/20/22 End: 07/31/24 Due: 07/31/25

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Phase: N/A Priority: Normal
NCT ID: NCT03755518 Org: User:
Start: 03/27/19 End: 11/08/23 Due: 11/08/24

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase: N/A Priority: Normal
NCT ID: NCT01197560 Org: User:
Start: 09/02/10 End: 04/05/18 Due: 04/05/19

A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00928486 Org: User:
Start: 04/28/09 End: 09/10/10 Due: 09/10/11

Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02250326 Org: User:
Start: 01/07/15 End: 08/17/23 Due: 08/17/24

A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT02367183 Org: User:
Start: 04/08/15 End: 12/14/17 Due: 12/14/18

A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.

Phase: N/A Priority: Normal
NCT ID: NCT02417285 Org: User:
Start: 05/22/15 End: 09/28/23 Due: 09/28/24

MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry

Phase: N/A Priority: Normal
NCT ID: NCT01347944 Org: User:
Start: 01/01/11 End: 06/30/13 Due: 06/30/14

Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function

Phase: N/A Priority: Normal
NCT ID: NCT04933747 Org: User:
Start: 08/12/21 End: 01/23/23 Due: 01/23/24

A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00864253 Org: User:
Start: 04/23/09 End: 02/12/14 Due: 02/12/15

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02189343 Org: User:
Start: 09/15/14 End: 04/30/18 Due: 04/30/19

A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03257631 Org: User:
Start: 09/18/17 End: 09/14/23 Due: 09/14/24

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT06045806 Org: User:
Start: 10/16/23 End: 08/11/25 Due: 08/11/26

Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active Metabolites

Phase: N/A Priority: Normal
NCT ID: NCT04149678 Org: User:
Start: 10/04/19 End: 12/26/19 Due: 12/26/20

Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00461045 Org: User:
Start: 03/31/07 End: 10/31/14 Due: 10/31/15